Skip to main content
Search
Twitter
Facebook
LinkedIn
Instagram
Español
Français
العربية
Toggle navigation
Members
Our Work
Our Response to COVID-19
Environment & ESCR
Corporate Accountability
Economic Policy
Monitoring
Social Movements
Strategic Litigation
System of Solidarity (SOS)
Women and ESCR
Common Charter
Resources
Introduction to ESCR
Resources
Caselaw Database
OP-ICESCR
Member News
Collective Work
About us
Who We Are
What We Do
Get Involved
India falla a favor de sus genéricos contra el cáncer, diez veces más baratos que los de Novartis, Público.es
URL:
http://www.publico.es/internacional/452930/india-falla-a-favor-de-sus-genericos-contra-el-cancer-diez-veces-mas-baratos-que-los-de-novartis